Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Merck & Co (NYSE:MRK) and its primary competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
Merck & Co Background Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
CompanyP/EP/BP/SROEEBITDA (in billions)Gross Profit (in billions)Revenue Growth| Merck & Co Inc | 914.21 | 8.63 | 5.42 | -3.11% | $-0.77 | $10.72 | 5.78% |
| Eli Lilly and Co | 135.21 | 69.22 | 20.76 | 19.91% | $3.03 | $7.57 | 28.1% |
| Novo Nordisk A/S | 46.52 | 36.27 | 16.76 | 22.01% | $28.51 | $55.85 | 36.95% |
| Johnson & Johnson | 29.31 | 5.34 | 4.58 | 5.78% | $6.82 | $14.6 | 7.3% |
| AstraZeneca PLC | 35.41 | 5.34 | 4.60 | 2.52% | $2.18 | $9.72 | 7.29% |
| Novartis AG | 23.36 | 4.20 | 4.29 | 19.99% | $4.18 | $8.75 | 7.39% |
| Pfizer Inc | 72.05 | 1.70 | 2.57 | -3.62% | $-1.77 | $6.69 | -41.34% |
| Sanofi SA | 20.29 | 1.47 | 2.36 | -0.75% | $0.42 | $8.15 | 6.5% |
| Bristol-Myers Squibb Co | 13.30 | 3.53 | 2.37 | 6.03% | $4.45 | $8.73 | 0.62% |
| GSK PLC | 13.58 | 4.98 | 2.21 | 2.64% | $1.16 | $5.63 | 9.16% |
| Zoetis Inc | 32.71 | 15.20 | 8.97 | 10.42% | $0.83 | $1.49 | 8.48% |
| Takeda Pharmaceutical Co Ltd | 36.72 | 0.96 | 1.56 | 1.53% | $314.89 | $731.71 | 1.33% |
| Viatris Inc | 236 | 0.68 | 0.92 | -3.7% | $-0.07 | $1.6 | -1.0% |
| Dr Reddy's Laboratories Ltd | 19.63 | 3.82 | 3.78 | 5.29% | $22.42 | $42.2 | 6.57% |
| Jazz Pharmaceuticals PLC | 19.10 | 1.94 | 2.19 | 2.61% | $0.29 | $0.9 | 4.1% |
| Corcept Therapeutics Inc | 26.82 | 5.15 | 5.84 | 6.43% | $0.03 | $0.13 | 31.39% |
| Average | 50.67 | 10.65 | 5.58 | 6.47% | $25.82 | $60.25 | 7.52% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } When conducting a detailed analysis of Merck & Co, the following trends become clear:
- The Price to Earnings ratio of 914.21 for this company is 18.04x above the industry average, indicating a premium valuation associated with the stock.
- With a Price to Book ratio of 8.63, significantly falling below the industry average by 0.81x, it suggests undervaluation and the possibility of untapped growth prospects.
- The Price to Sales ratio is 5.42, which is 0.97x the industry average. This suggests a possible undervaluation based on sales performance.
- The Return on Equity (ROE) of -3.11% is 9.58% below the industry average, suggesting potential inefficiency in utilizing equity to generate profits.
- With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $-770 Million, which is -0.03x below the industry average, the company may face lower profitability or financial challenges.
- The company has lower gross profit of $10.72 Billion, which indicates 0.18x below the industry average. This potentially indicates lower revenue after accounting for production costs.
- The company's revenue growth of 5.78% is significantly below the industry average of 7.52%. This suggests a potential struggle in generating increased sales volume.
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By considering the Debt-to-Equity ratio, Merck & Co can be compared to its top 4 peers, leading to the following observations:
- Compared to its top 4 peers, Merck & Co has a stronger financial position indicated by its lower debt-to-equity ratio of 0.93.
- This suggests that the company relies less on debt financing and has a more favorable balance between debt and equity, which can be seen as a positive attribute by investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.